Genmab buys antibodies from BMS
![](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article5717140.ece/ALTERNATES/schema-16_9/Genmab_logo_silver_on_green.jpg)
Genmab has entered into an agreement for an exclusive license from Bristol-Myers Squibb to a panel of human antibodies targeting CD19 together with associated intellectual property, the Danish-based biotech company says in a press release.
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Gilead to use Genmab drug in cancer combo
For abonnenter
Nordea: Analysts overlook daratumumab’s potential
For abonnenter
Genmab strikes deal with German biotech company
For abonnenter